Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Study Finds that LG Chem’s Biosimilar LBEC0101 is Comparable to Pfizer & Amgen’s Enbrel (Etanercept) for Treatment of Patients With Rheumatoid Arthritis

Mar 5, 2024

On 5 March 2024, a study published in Modern Rheumatology found that LG Chem’s LBEC0101, the biosimilar of etanercept, matches up to the reference product in terms of effectiveness and safety in the real-world treatment of rheumatoid arthritis. This evidence was gathered from the Kyoto University Rheumatoid Arthritis Management Alliance cohort, including patients treated between 2015 and 2021. The study reports that patients who switched from the reference product to LBEC0101 did not experience any significant differences in their treatment outcomes.